Search results
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 2 days agoReal-world study data suggest there is little difference among five drug classes commonly used to treat PsA in terms of their ability to improve both joint and skin symptoms.
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 2 hours agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
Izokibep Marches on for Psoriatic Arthritis
MedPage Today· 5 days agoAfter 16 weeks of treatment in the randomized, placebo-controlled study, 40% and 43% of patients receiving 160 mg of izokibep weekly or biweekly,...
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 2 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 2 days agoThe 25% figure confirms existing knowledge that up to a third will go on to develop psoriatic ...
What's in a Name: Defining Difficult-to-Treat axSpA and PsA
Medscape· 7 days agoDespite an expanding arsenal of disease-modifying antirheumatic drugs (DMARDs), many patients with...
Phase 3 Trial Supports Ixekizumab in Juvenile PsA, ERA
Medscape· 18 hours agoIxekizumab (Taltz), an interleukin-17A inhibitor that's already approved for the treatment of ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 9 hours agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque ...
Study led by UChicago Medicine physician finds new | Newswise
Newswise· 4 days agoA medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings ...
Beese Fulmer Investment Management Inc. Sells 137 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 14 hours agoBeese Fulmer Investment Management Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.6% during the first quarter, according to the company in its most recent 13F filing with ...